Peer-reviewedCC BY-NC-NDClinical and translational science
Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small-Molecule Oncology Drug Development.
- 1Clinical Pharmacology, Bristol Myers Squibb, Princeton, New Jersey, USA.
Related
- Bayesian Optimization for Dose Finding with Two Agents: Participant Allocation and Final Selection
- Valid Data‐Driven Subgroup Selection With Uniform Guarantees in Clinical Trials
- HALO: Hierarchical Evidence Selection and Reinforcement Learning for Allocating Budgeted Label Optimization from Longitudinal Clinical Records
- Methods for Assessing Distributional Assumptions in Individual Participant Data Meta-Analysis of Diagnostic Tests
- Influence of continuous predictor modelling methods on prediction stability in clinical prediction model development: an empirical comparison using real clinical data
BibTeX
@article{gupta2026healthy,
title = {{Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small-Molecule Oncology Drug Development.}},
author = {Paridhi Gupta and Zheyi Hu and Li Zhu and Lora Hamuro},
journal = {Clinical and translational science},
year = {2026},
month = nov,
doi = {10.1111/cts.70769},
url = {https://europepmc.org/article/MED/42967603},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small-Molecule Oncology Drug Development.
AU - Paridhi Gupta
AU - Zheyi Hu
AU - Li Zhu
AU - Lora Hamuro
PY - 2026
DA - 2026/11/01
JO - Clinical and translational science
DO - 10.1111/cts.70769
UR - https://europepmc.org/article/MED/42967603
SN - 1752-8054
SN - 1752-8062
ER -